The dengue virus (DENV) is a single-stranded RNA virus with increasing worldwide prevalence causing severe mosquito-borne viral infections. Therefore, effective strategies to prevent and treat DENV infections are urgently needed.

A recent study by scientists at Tongji University highlights the potential of TBAJ-587, a novel diarylquinoline, in addressing the challenge of treating Mycobacterium abscessus infections, a subset of nontuberculous mycobacteria that exhibit resistance to many antibiotics.

Institut Pasteur Korea has signed a memorandum of understanding (MOU) with four Pohang University of Science and Technology (POSTECH)-affiliated research institutes with the aim of pursuing joint research on mRNA vaccine and treatment development.

Novel vaccines that can effectively target both coronaviruses and influenza viruses would be desirable to counteract the significant health burden these respiratory pathogens pose.

Azole derivatives have been used as antifungal drugs in clinical practice for many years. However, limitations such as drug-drug interactions, severe adverse events from prolonged use, and high resistance prevalence highlight the urgent need for new therapeutic options to treat the rising number of invasive fungal infections.

First, the good news about pandemics – and in 2024, there was big “good news.” Science Magazine named lenacapavir (Gilead Sciences Inc.) as the Breakthrough of the Year. In two separate trials, lenacapavir prevented HIV transmission with 100% efficacy in cisgender African women and 99.9% efficacy in men and gender-diverse persons when administered twice a year.

Basilea Pharmaceutica Ltd. has been awarded an additional $7.3 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) to support the progression of the company’s novel antibiotic candidate, BAL-2420.